Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma

European Journal of Cancer

Volumn 39, Issue 13, 2003, Pages 1948-1956

  Manenti, L ^a   Paganoni, P ^a   Floriani, I ^b   Landoni, F ^c   Torri, V ^b   Buda, A ^c   Taraboletti, G ^a   Labianca, R ^d   Belotti, D ^a   Giavazzi, R ^a  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

^d OSPEDALI RIUNITI   (Italy)

Author keywords

MMP 2; MMP 9; Ovarian carcinoma; TIMP 1; TIMP 2; VEGF

Indexed keywords

GELATIN; GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; SIGNAL PEPTIDE; TUMOR MARKER; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; ZYMOGRAPHY; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; METABOLISM; MIDDLE AGED; OVARY TUMOR; PROGNOSIS; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; ENDOTHELIAL GROWTH FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0141778596     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00427-1     Document Type: Article

References (48)

1. Parker S.L., Tong T., Bolden S., Wingo P.A. Cancer statistics. CA Cancer J Clin. 47:1997;5-27.
2. Ozols R., Rubin S., Thomas G., Robboy S. Epithelial ovarian cancer. WJ H., CA P., RC Y. Principles and Practice of Gynecologic Oncology. 2000;981-999 Lippincott Williams and Wilkins, Baltimore, MD.
3. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature. 407:2000;49-57.
4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:1995;27-31.
5. Barton D.P., Cai A., Wendt K., Young M., Gamero A., De Cesare S. Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res. 3:1997;1579-1586.
6. Fujimoto J., Sakaguchi H., Hirose R., Ichigo S., Tamaya T. Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma. Cancer. 83:1998;2528-2533.
7. Tempfer C., Obermair A., Hefler L., Haeusler G., Gitsch G., Kainz C. Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol. 92:1998;360-363.
8. Kraft A., Weindel K., Ochs A.et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 85:1999;178-187.
9. Yamamoto S., Konishi I., Mandai M.et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms. correlation with clinicopathology and patient survival, and analysis of serum VEGF levels Br J Cancer. 76:1997;1221-1227.
10. Poon R.T., Fan S.T., Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 19:2001;1207-1225.
11. Chen C.A., Cheng W.F., Lee C.N.et al. Serum vascular endothelial growth factor in epithelial ovarian neoplasms. correlation with patient survival Gynecol Oncol. 74:1999;235-240.
12. Oehler M.K., Caffier H. Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Anticancer Res. 20:2000;5109-5112.
13. Nagy J.A., Masse E.M., Herzberg K.T.et al. Pathogenesis of ascites tumour growth. vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation Cancer Res. 55:1995;360-368.
14. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 146:1995;1029-1039.
15. Xu L., Yoneda J., Herrera C., Wood J., Killion J.J., Fidler I.J. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol. 16:2000;445-454.
16. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:2002;161-174.
17. Liotta L.A., Stetler-Stevenson W.G. Tumor invasion and metastasis. an imbalance of positive and negative regulation Cancer Res. 51:1991;5054s-5059s.
18. Matrisian L.M. Cancer biology. extracellular proteinases in malignancy Curr Biol. 9:1999;R776-R778.
19. Kallakury B.V., Karikehalli S., Haholu A., Sheehan C.E., Azumi N., Ross J.S. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 7:2001;3113-3119.
20. Scorilas A., Karameris A., Arnogiannaki N.et al. Overexpression of matrix-metalloproteinase-9 in human breast cancer. a potential favourable indicator in node-negative patients Br J Cancer. 84:2001;1488-1496.
21. Vihinen P., Kahari V.M. Matrix metalloproteinases in cancer. prognostic markers and therapeutic targets Int J Cancer. 99:2002;157-166.
22. Garzetti G.G., Ciavattini A., Lucarini G.et al. Expression of vascular endothelial growth factor related to 72-kilodalton metalloproteinase immunostaining in patients with serous ovarian tumours. Cancer. 85:1999;2219-2225.
23. Lengyel E., Schmalfeldt B., Konik E.et al. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol. 82:2001;291-298.
24. Davidson B., Goldberg I., Gotlieb W.H.et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis. 17:1999;799-808.
25. Giavazzi R., Garofalo A., Ferri C.et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumour activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res. 4:1998;985-992.
26. Denhardt D.T., Feng B., Edwards D.R., Cocuzzi E.T., Malyankar U.M. Tissue inhibitor of metalloproteinases (TIMP, aka EPA). structure, control of expression and biological functions Pharmacol Ther. 59:1993;329-341.
27. Khokha R. Suppression of the tumourigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst. 86:1994;299-304.
28. Gomez D.E., Alonso D.F., Yoshiji H., Thorgeirsson U.P. Tissue inhibitors of metalloproteinases. structure, regulation and biological functions Eur J Cell Biol. 74:1997;111-122.
29. Ring P., Johansson K., Hoyhtya M., Rubin K., Lindmark G. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer - a predictor of tumour stage. Br J Cancer. 76:1997;805-811.
30. Yoshikawa T., Saitoh M., Tsuburaya A.et al. Tissue inhibitor of matrix metalloproteinase-1 in the plasma of patients with gastric carcinoma. A possible marker for serosal invasion and metastasis. Cancer. 86:1999;1929-1935.
31. Int J Gynecol Obstet. 28:1989;189-193.
32. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer Oct. 2:2002;727-739.
33. Cooper B.C., Ritchie J.M., Broghammer C.L.et al. Preoperative serum vascular endothelial growth factor levels. significance in ovarian cancer Clin Cancer Res. 8:2002;3193-3197.
34. Gadducci A., Ferdeghini M., Fanucchi A.et al. Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer. relationship with prognostic variables and clinical outcome Anticancer Res. 19:1999;1401-1405.
35. Verheul H.M., Hoekman K., Luykx-de Bakker S.et al. Platelet. transporter of vascular endothelial growth factor Clin Cancer Res. 3:1997;2187-2190.
36. Banks R.E., Forbes M.A., Kinsey S.E.et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets. significance for VEGF measurements and cancer biology Br J Cancer. 77:1998;956-964.
37. Wynendaele W., Derua R., Hoylaerts M.F.et al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers. a key to study an angiogenic marker in vivo? Ann Oncol. 10:1999;965-971.
38. Monreal M., Fernandez-Llamazares J., Pinol M.et al. Platelet count and survival in patients with colorectal cancer - a preliminary study. Thromb Haemost. 79:1998;916-918.
39. Menczer J., Schejter E., Geva D., Ginath S., Zakut H. Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival. Eur J Gynaecol Oncol. 19:1998;82-84.
40. Pinedo H.M., Verheul H.M., D'Amato R.J., Folkman J. Involvement of platelets in tumour angiogenesis? Lancet. 352:1998;1775-1777.
41. Verheul H.M., Jorna A.S., Hoekman K., Broxterman H.J., Gebbink M.F., Pinedo H.M. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood. 96:2000;4216-4221.
42. Polette M., Gilbert N., Stas I.et al. Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Arch. 424:1994;641-645.
43. Huang S., Van Arsdall M., Tedjarati S.et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst. 94:2002;1134-11342.
44. Lane W.J., Dias S., Hattori K.et al. Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood. 96:2000;4152-4159.
45. Campo E., Tavassoli F.A., Charonis A., Stetler-Stevenson W.G., Liotta L.A., Merino M.J. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumours of the ovary. Am J Pathol. 6:1992;500-507.
46. DeClerck Y.A. Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer. Eur J Cancer. 36:2000;1258-1268.
47. Baker T., Tickle S., Wasan H., Docherty A., Isenberg D., Waxman J. Serum metalloproteinases and their inhibitors. markers for malignant potential Br J Cancer. 70:1994;506-512.
48. McCarthy K., Maguire T., McGreal G., McDermott E., O'Higgins N., Duffy M.J. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer. 84:1999;44-48.